{"id":384933,"date":"2020-11-19T08:03:26","date_gmt":"2020-11-19T13:03:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384933"},"modified":"2020-11-19T08:03:26","modified_gmt":"2020-11-19T13:03:26","slug":"cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/","title":{"rendered":"Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) — Cue Biopharma, Inc.<\/a> (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient\u2019s body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease.<\/p>\n

\u201cWe are very pleased with the progress to date in our ongoing strategic collaboration with Merck,\u201d said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. \u201cExtending the research term of our agreement based on promising preclinical data with a goal of identifying a clinical candidate underscores the significant potential of our therapeutic Immuno-STAT\u2122 (Selective Targeting and Alteration of T cells)<\/em> platform and CUE-300 series in the treatment of debilitating autoimmune diseases.\u201d<\/p>\n

Under the terms of the extension, Cue Biopharma will receive additional financial research support to further study and develop promising preclinical biologics with the objective of identifying clinical candidates.<\/p>\n

Cue Biopharma entered into an exclusive patent license and research collaboration agreement with Merck in November 2017 to develop biologics for the treatment of selected autoimmune diseases. For further information regarding the amendment, please refer to the Current Report on Form 8-K to be filed by Cue Biopharma with the SEC on November 19, 2020.<\/p>\n

\n About Immuno-STAT<\/strong>
\n
Immuno-STAT\u2122 biologics are being designed for targeted modulation of disease-associated T cells in the areas of immuno-oncology and autoimmune disease. Each of our biologic drug candidates is designed using our proprietary scaffold comprising: 1) a peptide-MHC complex (pMHC) to provide selectivity through interaction with the T cell receptor (TCR), and 2) a unique co-stimulatory signaling molecule to modulate the activity of the target T cells.<\/p>\n

The simultaneous engagement of co-regulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in highly targeted T cell modulation. Because our drugs are delivered directly in the patient\u2019s body (in vivo), they are fundamentally different from other T cell therapeutic approaches that require the patients\u2019 T cells to be extracted, modified outside the body (ex vivo), and reinfused.<\/p>\n

\n About\u00a0Cue Biopharma<\/strong>
\n
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient\u2019s body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company\u2019s proprietary platform, Immuno-STAT\u2122 (Selective Targeting and Alteration of T cells)<\/em> is designed to harness the body\u2019s intrinsic immune system without the need for ex vivo manipulation.<\/p>\n

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.<\/p>\n

For more information, visit\u00a0www.cuebiopharma.com<\/a>\u00a0and follow us on Twitter https:\/\/twitter.com\/CueBiopharma<\/a>.<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the goal of identifying a clinical candidate under the Merck collaboration; the potential of the Immuno-STAT platform and CUE-300 series to treat autoimmune diseases; the anticipated results of the company\u2019s drug development efforts, including study results; and the company\u2019s expectations regarding regulatory developments and expected future operating results. Forward-looking statements, which are based on certain assumptions and describe the company\u2019s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cseek,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cgoal,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201clikely\u201d or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company\u2019s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company\u2019s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company\u2019s limited operating history, limited cash and a history of losses; the company\u2019s ability to achieve profitability; potential setbacks in the company\u2019s research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required\u00a0U.S. Food and Drug Administration\u00a0(\u201cFDA\u201d) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the company\u2019s operations and clinical trials; negative or inconclusive results from the company\u2019s clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the\u00a0FDA; the company\u2019s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company\u2019s ability to obtain adequate financing to fund its business operations in the future; ; the company\u2019s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company\u2019s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n

\n Investor Contact <\/strong>
\n
George B. Zavoico, Ph.D.
VP, Investor Relations & Corporate Development
Cue Biopharma, Inc.
gzavoico@cuebio.com<\/a><\/p>\n

\n Media Contact<\/strong>
\n
Alison Chen
LifeSci Communications
achen@lifescicomms.com<\/a>\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient\u2019s body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease. \u201cWe are very pleased with the progress to date in our ongoing strategic collaboration with Merck,\u201d said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. \u201cExtending the research term of our agreement based on promising preclinical data with a … <\/p>\n

Continue reading “Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384933","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient\u2019s body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease. \u201cWe are very pleased with the progress to date in our ongoing strategic collaboration with Merck,\u201d said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. \u201cExtending the research term of our agreement based on promising preclinical data with a … Continue reading "Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T13:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcwOSMzODIyOTE3IzIwOTI2OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck\",\"datePublished\":\"2020-11-19T13:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\\\/\"},\"wordCount\":1076,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODcwOSMzODIyOTE3IzIwOTI2OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\\\/\",\"name\":\"Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODcwOSMzODIyOTE3IzIwOTI2OTI=\",\"datePublished\":\"2020-11-19T13:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODcwOSMzODIyOTE3IzIwOTI2OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODcwOSMzODIyOTE3IzIwOTI2OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/","og_locale":"en_US","og_type":"article","og_title":"Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient\u2019s body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease. \u201cWe are very pleased with the progress to date in our ongoing strategic collaboration with Merck,\u201d said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. \u201cExtending the research term of our agreement based on promising preclinical data with a … Continue reading \"Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T13:03:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcwOSMzODIyOTE3IzIwOTI2OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck","datePublished":"2020-11-19T13:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/"},"wordCount":1076,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcwOSMzODIyOTE3IzIwOTI2OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/","name":"Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcwOSMzODIyOTE3IzIwOTI2OTI=","datePublished":"2020-11-19T13:03:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcwOSMzODIyOTE3IzIwOTI2OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODcwOSMzODIyOTE3IzIwOTI2OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-extends-research-collaboration-for-the-development-of-immuno-stat-biologics-for-the-treatment-of-defined-autoimmune-diseases-with-merck\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384933"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384933\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}